Stopping drug treatment in schizophrenia
Author information unavailable
Abstract
Author information unavailable
Abstract
Patients with schizophrenic illnesses often fail to make a full recovery. Only about 25% of patients in western countries remain symptom-free after recovery from a first episode of acute schizophrenia.1–3 Antipsychotic medication suppresses symptoms and reduces the frequency of relapse, but the continuing underlying illness will cause many schizophrenics to relapse when these drugs are stopped. This article assesses the long-term benefits and risks of continuing or discontinuing antipsychotic therapy for schizophrenia.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Patients with schizophrenic illnesses often fail to make a full recovery. Only about 25% of patients in western countries remain symptom-free after recovery from a first episode of acute schizophrenia.1–3 Antipsychotic medication suppresses symptoms and reduces the frequency of relapse, but the continuing underlying illness will cause many schizophrenics to relapse when these drugs are stopped. This article assesses the long-term benefits and risks of continuing or discontinuing antipsychotic therapy for schizophrenia.
Key concepts: Schizophrenia (object-oriented programming), Psychiatry, Antipsychotic, Antipsychotic drug, Medicine, Intensive care medicine